-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Non-small cell lung cancer ( NSCLC ) accounts for approximately 85% of lung cancer diagnoses
.
Anaplastic lymphoma kinase (ALK) gene rearrangement occurs in approximately 3.
Non-small cell lung cancer ( NSCLC ) accounts for approximately 85% of lung cancer diagnoses
Crizotinib is the first generation ALK tyrosine kinase inhibitor (TKI) and the first drug specifically approved for this patient.
UVEA-Brig is a multi-center retrospective study conducted abroad to evaluate the efficacy of brigatinib after the progress of ALK + NSCLC patients with ALK inhibitors
A total of 104 patients , (male: 43%; median age: 53[29 80] years; ECOG score 0/1/2/3: 41/ 41/10/5%; brain/central nervous system metastasis: 63 %) .
The median follow-up was 16.
5 months .
34 patients received first-line ALK-TKI treatment, and most of them received first-line chemotherapy .
Before using 81 patients received at least Bucharest erlotinib treatment system 2 in 69 patients (85%) received second-line ALK TKI (gefitinib g oxadiazol 57 is embodiment , the plug Swiss imatinib 11 cases , workers pull gefitinib 1 case ) .
Of the 104 patients, 74 (71%) received radiotherapy .
The median follow-up was 16.
5 months .
34 patients received first-line ALK-TKI treatment, and most of them received first-line chemotherapy .
Before using 81 patients received at least Bucharest erlotinib treatment system 2 in 69 patients (85%) received second-line ALK TKI (gefitinib g oxadiazol 57 is embodiment , the plug Swiss imatinib 11 cases , workers pull gefitinib 1 case ) .
Of the 104 patients, 74 (71%) received radiotherapy .
Previous treatment drugs
Past treatment drugs Past treatment drugsThe total median duration of brigatinib treatment was 16.
5 months (95% CI: 12.
9 to 18.
5); at the time of data analysis , 27 patients were still receiving brigatinib treatment
The total median duration of brigatinib treatment was 16.
Efficacy evaluation
Efficacy assessment Efficacy assessmentPFS and OS
PFS and OS PFS and OS57 out of 65 patients with brain/central nervous system metastases can be evaluated
.
Among 57 patients, 23 patients (40.
57 out of 65 patients with brain/central nervous system metastases can be evaluated
At the time of analysis, 77 patients had discontinued brigatinib treatment, with a median discontinuation time of 8.
In summary, after ALK + NSCLC patients use ALK inhibitors, taking brigatinib is still effective and the toxicity is tolerable
Original source:
P opat S, Brustugun OT, Cadranel J, et al .
P opat S, Brustugun OT, Cadranel J, et al .
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
Lung Cancer.
2021 Jul;157:9-16.
doi: 10.
1016/j .
lungcan.
2021.
05.
017.
Epub 2021 May 24.
PMID: 34051652.
P opat S, Brustugun OT, Cadranel J, et al .
Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
Lung Cancer.
2021 Jul;157:9-16.
doi: 10.
1016/j.
lungcan.
2021.
05.
017.
Epub 2021 May 24.
PMID: 34051652.
Leave a message here